Royalty Pharma plc Stock-Based Compensation
Royalty Pharma plc (RPRX) reported Stock-Based Compensation of $229.06 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-05
- Royalty Pharma plc share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $107.07M, a 17.96% increase year-over-year.
- Royalty Pharma plc share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $121.99M, a 23587.77% increase year-over-year.
- Royalty Pharma plc share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $125.77M, a 23855.81% increase year-over-year.
- Royalty Pharma plc share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $72.84M, a 13748.29% increase year-over-year.
- Royalty Pharma plc share-based payment arrangement, noncash expense for fiscal 2025 was $289.89M, a 12267.49% increase from fiscal 2024.
- Royalty Pharma plc share-based payment arrangement, noncash expense for fiscal 2024 was $2.34M, a 0.55% decline from fiscal 2023.
- Royalty Pharma plc share-based payment arrangement, noncash expense for fiscal 2023 was $2.36M, a 8.62% increase from fiscal 2022.
- Royalty Pharma plc share-based payment arrangement, noncash expense for fiscal 2022 was $2.17M, a 11.17% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $107.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $229.06M 10-Q · filed 2026-08-05 | $354.83M derived: sum of 3 quarters · filed 2026-08-05 | $427.67M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $121.99M 10-Q · filed 2026-05-06 | $247.76M derived: sum of 2 quarters · filed 2026-05-06 | $320.60M derived: sum of 3 quarters · filed 2026-05-06 | $411.37M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $125.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $198.61M derived: sum of 2 quarters · filed 2026-02-11 | $289.38M derived: sum of 3 quarters · filed 2026-08-05 | $289.89M 10-K · filed 2026-02-11 |
| 2025-09-30 | $72.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $163.61M derived: sum of 2 quarters · filed 2026-08-05 | $164.13M 10-Q · filed 2025-11-05 | $164.65M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $90.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $91.28M 10-Q · filed 2026-08-05 | $91.81M derived: sum of 3 quarters · filed 2026-08-05 | $92.33M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $515.00K 10-Q · filed 2026-05-06 | $1.04M derived: sum of 2 quarters · filed 2026-05-06 | $1.57M derived: sum of 3 quarters · filed 2026-05-06 | $2.25M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $525.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $1.05M derived: sum of 2 quarters · filed 2026-02-11 | $1.73M derived: sum of 3 quarters · filed 2026-02-11 | $2.34M 10-K · filed 2026-02-11 |
| 2024-09-30 | $526.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $1.21M derived: sum of 2 quarters · filed 2025-11-05 | $1.82M 10-Q · filed 2025-11-05 | $2.44M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-06-30 | $681.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $1.29M 10-Q · filed 2025-08-06 | $1.91M derived: sum of 3 quarters · filed 2026-02-11 | $2.49M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-03-31 | $612.00K 10-Q · filed 2025-05-08 | $1.23M derived: sum of 2 quarters · filed 2026-02-11 | $1.81M derived: sum of 3 quarters · filed 2026-02-11 | $2.40M derived: sum of 4 quarters · filed 2026-02-11 |
| 2023-12-31 | $617.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $1.20M derived: sum of 2 quarters · filed 2026-02-11 | $1.78M derived: sum of 3 quarters · filed 2026-02-11 | $2.36M 10-K · filed 2026-02-11 |
| 2023-09-30 | $581.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $1.17M derived: sum of 2 quarters · filed 2024-11-06 | $1.74M 10-Q · filed 2024-11-06 | $2.32M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-06-30 | $586.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $1.16M 10-Q · filed 2024-08-08 | $1.74M derived: sum of 3 quarters · filed 2025-02-12 | $2.32M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-03-31 | $573.00K 10-Q · filed 2024-05-09 | $1.16M derived: sum of 2 quarters · filed 2025-02-12 | $1.74M derived: sum of 3 quarters · filed 2025-02-12 | $2.25M derived: sum of 4 quarters · filed 2025-02-12 |
| 2022-12-31 | $583.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $1.17M derived: sum of 2 quarters · filed 2025-02-12 | $1.67M derived: sum of 3 quarters · filed 2025-02-12 | $2.17M 10-K · filed 2025-02-12 |
| 2022-09-30 | $582.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $1.09M derived: sum of 2 quarters · filed 2023-11-08 | $1.59M 10-Q · filed 2023-11-08 | $2.09M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | $509.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $1.00M 10-Q · filed 2023-08-08 | $1.51M derived: sum of 3 quarters · filed 2024-02-15 | $2.01M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | $496.00K 10-Q · filed 2023-05-09 | $1.00M derived: sum of 2 quarters · filed 2024-02-15 | $1.50M derived: sum of 3 quarters · filed 2024-02-15 | $2.23M derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | $504.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $1.01M derived: sum of 2 quarters · filed 2024-02-15 | $1.73M derived: sum of 3 quarters · filed 2024-02-15 | $2.44M 10-K · filed 2024-02-15 |
| 2021-09-30 | $505.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $1.23M derived: sum of 2 quarters · filed 2022-11-08 | $1.94M 10-Q · filed 2022-11-08 | $2.78M derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-06-30 | $721.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $1.43M 10-Q · filed 2022-08-04 | $2.27M derived: sum of 3 quarters · filed 2023-02-15 | $3.12M derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-03-31 | $713.00K 10-Q · filed 2022-05-05 | $1.55M derived: sum of 2 quarters · filed 2023-02-15 | $2.40M derived: sum of 3 quarters · filed 2023-02-15 | $6.14M derived: sum of 4 quarters · filed 2023-02-15 |
| 2020-12-31 | $840.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | $1.69M derived: sum of 2 quarters · filed 2023-02-15 | $5.43M derived: sum of 3 quarters · filed 2023-02-15 | $5.43M 10-K · filed 2023-02-15 |
| 2020-09-30 | $848.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $4.59M derived: sum of 2 quarters · filed 2021-11-10 | $4.59M 10-Q · filed 2021-11-10 | $4.59M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-06-30 | $3.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $3.74M 10-Q · filed 2021-08-11 | $3.74M derived: sum of 3 quarters · filed 2022-02-15 | $3.74M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-03-31 | $0.00 10-Q · filed 2021-05-11 | $0.00 derived: sum of 2 quarters · filed 2022-02-15 | $0.00 derived: sum of 3 quarters · filed 2022-02-15 | |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $0.00 derived: sum of 2 quarters · filed 2022-02-15 | $0.00 10-K · filed 2022-02-15 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $0.00 10-Q · filed 2020-11-12 | ||
| 2019-06-30 | $0.00 10-Q · filed 2020-08-12 | |||
| 2018-12-31 | $0.00 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |